日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Study of key residues in MERS-CoV and SARS-CoV-2 main proteases for resistance against clinically applied inhibitors nirmatrelvir and ensitrelvir

MERS-CoV 和 SARS-CoV-2 主要蛋白酶中关键残基对临床应用抑制剂尼玛瑞韦和恩西瑞韦耐药性的研究

Laura Krismer, Helge Schöppe #, Stefanie Rauch #, David Bante, Bernhard Sprenger, Andreas Naschberger, Francesco Costacurta, Anna Fürst, Anna Sauerwein, Bernhard Rupp, Teresa Kaserer, Dorothee von Laer, Emmanuel Heilmann

Vesicular Stomatitis Virus as a Platform for Protease Activity Measurements

水泡性口炎病毒作为蛋白酶活性测量的平台

Stefanie Rauch, Francesco Costacurta, Dorothee von Laer, Emmanuel Heilmann

SARS-CoV-2 3CLpro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376

在基于 VSV 的系统中筛选出的 SARS-CoV-2 3CLpro 突变导致对尼玛瑞韦、恩西瑞韦和 GC376 产生耐药性

Emmanuel Heilmann, Francesco Costacurta, Seyed Arad Moghadasi, Chengjin Ye, Matteo Pavan, Davide Bassani, Andre Volland, Claudia Ascher, Alexander Kurt Hermann Weiss, David Bante, Reuben S Harris, Stefano Moro, Bernhard Rupp, Luis Martinez-Sobrido, Dorothee von Laer

Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors

对临床蛋白酶抑制剂具有耐药性的可传播 SARS-CoV-2 变体

Seyed Arad Moghadasi, Emmanuel Heilmann, Ahmed Magdy Khalil, Christina Nnabuife, Fiona L Kearns, Chengjin Ye, Sofia N Moraes, Francesco Costacurta, Morgan A Esler, Hideki Aihara, Dorothee von Laer, Luis Martinez-Sobrido, Timothy Palzkill, Rommie E Amaro, Reuben S Harris

A VSV-based assay quantifies coronavirus Mpro/3CLpro/Nsp5 main protease activity and chemical inhibition

基于 VSV 的检测方法可量化冠状病毒 Mpro/3CLpro/Nsp5 主要蛋白酶活性和化学抑制

Emmanuel Heilmann, Francesco Costacurta #, Stephan Geley #, Seyad Arad Mogadashi #, Andre Volland #, Bernhard Rupp, Reuben Stewart Harris, Dorothee von Laer